At the 2026 Dermatology Summit, the Entrepreneurial Company Showcase will spotlight companies driving the next wave of dermatology innovation. These sessions offer investors, strategic partners, and entrepreneurs a front-row seat to science and technology shaping the future of skin health. Expect succinct, data-driven presentations that illuminate clinical relevance, regulatory path, and commercial potential, spanning advanced topical delivery, gene-based aesthetics, dermato-oncology, hair biology, microbiome therapeutics, and senescence science. If you’re building or partnering in skin health, this is where the most promising science and strategy in dermatology come into focus.
This year's 2026 guests include:
Amplifica is a biopharmaceutical company focused on developing novel treatments to address androgenetic alopecia, a condition affecting tens of millions of men and women globally. They are taking a nature-inspired scientific approach using a molecular mechanism that regrows natural hair. Their lead candidate, AMP-303, is currently in early clinical trials as a non-hormonal injectable treatment to reactivate dormant hair follicles. Amplifica offers an exciting example of how hair and scalp dermatology is being re-imagined. https://amplificabio.com/
Dermaliq is a clinical-stage dermatology and medical aesthetics company developing a new generation of topical therapies that deliver active compounds deeply into skin and follicular tissues by using its proprietary hyliQ® technology platform. This platform has potential for broad application across dermatology and rare disease indications. Their lead candidate DLQ01 reported statistically significant topline data in a Phase 1b/2a trial for androgenetic alopecia in men, and they are collaborating with DEBRA Research to explore advanced topical delivery for fragile skin in epidermolysis bullosa using the hyliQ® system. https://dermaliq.com/
Evommune is a clinical-stage biotechnology company developing novel therapies for chronic immune-mediated inflammatory diseases with significant unmet need. Its lead program, EVO756, is a first-in-class oral MRGPRX2 antagonist that has shown positive Phase 2 results in chronic inducible urticaria, with Phase 2b development underway for chronic spontaneous urticaria and atopic dermatitis. Their recent IPO highlights strong investor interest and positions the company as one to watch in mast-cell–driven inflammatory disease. https://www.evommune.com/
Highlight Therapeutics is a private clinical-stage dermato-oncology company developing double-stranded RNA–based intratumoral immunotherapies. Their lead candidate, BO-112, is designed to convert immunologically “cold” tumors into “hot” ones for immune attack. BO-112 is being investigated in monotherapy for treatment of primary basal cell carcinoma and in combination with immune-checkpoint inhibitors and radiotherapy for sarcomas and non-small cell lung cancer. https://www.highlighttherapeutics.com/
Jeune, a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging or photo-damaged skin. In a Phase 1 study, KB304, an investigational aesthetic therapy, showed positive safety and efficacy results. KB304 employs this novel approach to deliver two copies of the gene encoding COL3 transgene and one copy of the gene encoding elastin to increase their levels in skin and address signs of skin aging associated with damage to the skin’s extracellular matrix. https://jeuneinc.com/
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Their proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Lead drug candidate, RLS-1496, a potential first-in-class disease-modifying selective GPX4 modulator is currently in Phase I clinical trials. https://www.rubedolife.com/
Join us this January to hear directly from these and other companies leading the next wave of dermatology innovation. Secure your seat today!
